Krystal Biotech
KRYS
324.57
-2.24
-0.69%
Krystal Biotech
US · KRYS
#1515 by market cap
Listed 2017
324.57
-2.24
-0.69%
Live - 5344 symbols - heartbeat 53s ago
· 2026-10-08 05:56
Pre-market
324.57
0.00%
After-hours
324.57
0.00%
- Market cap
- 9.61B
- P/E (TTM)i
- 40.67
- P/Bi
- 7.07
- EPSi
- 6.84
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on KRYS?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
409.29 +26.1%
Price target rangecurrent 324.57
Low361.00
Avg409.29
High474.00
Buy 89%
Hold 11%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-24 | Goldman Sachs | -- | BUY | 441.00 |
| 2026-09-21 | BofA Securities | -- | BUY | 400.00 |
| 2026-08-14 | RBC Capital | -- | BUY | 400.00 |
| 2026-08-11 | Wolfe Research | -- | HOLD | -- |
| 2026-08-04 | Citi | -- | BUY | 386.00 |
| 2026-08-03 | TD Cowen | -- | BUY | 403.00 |
| 2026-08-03 | William Blair | -- | BUY | -- |
| 2026-08-03 | BofA Securities | -- | BUY | 392.00 |
| 2026-08-03 | H.C. Wainwright | -- | BUY | 361.00 |
| 2026-07-22 | William Blair | -- | BUY | -- |
| 2026-07-13 | BofA Securities | -- | BUY | 396.00 |
| 2026-07-13 | Jefferies | -- | BUY | 474.00 |
| 2026-06-18 | TD Cowen | -- | BUY | 403.00 |
| 2026-06-17 | H.C. Wainwright | -- | BUY | 361.00 |
| 2026-06-16 | H.C. Wainwright | -- | BUY | 361.00 |
| 2026-06-01 | H.C. Wainwright | -- | BUY | 310.00 |
| 2026-05-31 | BofA Securities | -- | BUY | 364.00 |
| 2026-05-22 | BofA Securities | -- | BUY | 364.00 |
| 2026-05-22 | H.C. Wainwright | -- | BUY | 310.00 |
| 2026-05-18 | William Blair | -- | BUY | -- |
| 2026-05-18 | H.C. Wainwright | -- | BUY | 310.00 |
| 2026-05-14 | BofA Securities | -- | BUY | -- |
| 2026-05-05 | Evercore | -- | BUY | 300.00 |
| 2026-05-05 | Citi | -- | BUY | 378.00 |
| 2026-05-04 | TD Cowen | -- | BUY | 306.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Citi moved from Hold to Buy on 2026-01-06.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-01-06 | Citi | HOLD → BUY | 309.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-03 | -- | ±10.66% | -8.37% (in line) |
| 2026/Q1 | 2026-05-04 | -- | ±8.29% | +7.86% (in line) |
| 2025/Q4 | 2026-02-17 | -- | ±8.15% | +4.12% (in line) |
| 2025/Q3 | 2025-11-03 | -- | ±11.42% | +0.17% (in line) |
| 2025/Q2 | 2025-08-04 | -- | ±11.51% | -14.04% (beat) |
| 2025/Q1 | 2025-05-06 | -- | ±11.04% | -14.06% (beat) |
| 2024/Q4 | 2025-02-19 | -- | ±13.26% | +12.43% (in line) |
| 2024/Q3 | 2024-11-04 | -- | ±13.93% | -3.14% (in line) |
| 2024/Q2 | 2024-08-05 | -- | ±15.03% | -5.85% (in line) |
| 2024/Q1 | 2024-05-06 | -- | ±13.03% | -2.58% (in line) |
| 2023/Q4 | 2024-02-26 | -- | ±16.98% | +41.02% (beat) |
| 2023/Q3 | 2023-11-06 | -- | -- | -15.05% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 05:56:28 · For reference only, not investment advice and not tailored to your situation.